New peptides for imaging and treating aggressive breast cancer
Novel MUC1 Theranostic Peptides for Imaging and Treatment of Triple-Negative Breast Cancer
This study is looking at new ways to treat triple-negative breast cancer by using special proteins that can deliver targeted radiation directly to the cancer cells, helping to make the treatment more effective and less harmful to healthy tissue.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11010025 on NIH RePORTER |
What this research studies
This research focuses on developing novel peptides that target MUC1, a protein overexpressed in triple-negative breast cancer (TNBC). The approach combines targeted radionuclide therapy (TRT) with these peptides to deliver localized radiation specifically to cancer cells while minimizing damage to normal tissues. By enhancing the effectiveness of treatment and reducing side effects, this research aims to improve outcomes for patients with TNBC. The study will involve creating and testing these peptides for their potential use in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who are seeking new treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who do not have MUC1 overexpression may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in using targeted therapies for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Beinat, Corinne — Stanford University
- Study coordinator: Beinat, Corinne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.